CLINICAL MANAGEMENT OF RECURRENT CANDIDIASIS: WHAT DOES THE EVIDENCE SAY?

• DOI: https://doi.org/10.22533/at.ed.15944724290510

• Palavras-chave: Candidiasis; Antifungals; Fluconazole

• Keywords: Candidiasis; Antifungals; Fluconazole

• Abstract:

  Recurrent vulvovaginal candidiasis (RVC) is a common condition affecting many women, characterized by frequent episodes of Candida infection. Although azoles are often prescribed as initial treatment, resistance to these drugs is becoming a growing concern. Furthermore, management of CVR can be challenging due to a lack of effective therapeutic options. Alternative strategies, such as immunotherapy and behavioral therapies, are being investigated but still lack conclusive evidence. The treatment approach should consider not only the eradication of acute infection, but also the prevention of recurrences through identification and elimination of underlying risk factors. An in-depth understanding of resistance mechanisms and host-pathogen interactions is essential for the development of new, more effective and safer therapeutic approaches for CVR.